Title | Predicting complications in pre-eclampsia: external validation of the fullPIERS model using the PETRA trial dataset. |
Publication Type | Journal Article |
Year of Publication | 2014 |
Authors | Akkermans, J, Payne, BA, von Dadelszen, P, Groen, H, de Vries, J, Magee, LA, Mol, B, Ganzevoort, J |
Journal | Eur J Obstet Gynecol Reprod Biol |
Volume | 179 |
Pagination | 58-62 |
Date Published | 2014 Aug |
ISSN | 1872-7654 |
Keywords | Eclampsia, Female, Fetal Growth Retardation, HELLP Syndrome, Humans, PIERS, Pre-Eclampsia, Predictive Value of Tests, Pregnancy, Pregnancy Outcome, Prognosis, Prospective Studies, Risk Factors, ROC Curve |
Abstract | OBJECTIVE: The internally validated fullPIERS model predicts adverse maternal outcomes in women with pre-eclampsia within 48h after eligibility. Our objective was to assess generalizability of this prediction model. STUDY DESIGN: External validation study using prospectively collected data from two tertiary care obstetric centers. METHODS: The existing PETRA dataset, a cohort of women (n=216) with severe early-onset pre-eclampsia, eclampsia, HELLP syndrome or hypertension-associated fetal growth restriction was used. The fullPIERS model equation was applied to all women in the dataset using values collected within 48h after inclusion. The performance (ROC area and R-squared) of the model, risk stratification and calibration were assessed from 48h up to a week after inclusion. RESULTS: Of 216 women in the PETRA trial, 73 (34%) experienced an adverse maternal outcome(s) at any time after inclusion. Adverse maternal outcome was observed in 32 (15%) cases within 48h and 62 (29%) within 7 days after inclusion. The fullPIERS model predicted adverse maternal outcomes within 48h (AUC ROC 0.97, 95% CI: 0.87-0.99) and up to 7 days after inclusion (AUC ROC 0.80, 95% CI: 0.70-0.87). CONCLUSIONS: The fullPIERS model performed well when applied to the PETRA dataset. These results confirm the usability of the fullPIERS prediction model as a 'rule-in' test for women admitted with severe pre-eclampsia, eclampsia, HELLP syndrome or hypertension-associated fetal growth restriction. Future research should focus on intervention studies that assess the clinical impact of strategies using the fullPIERS model. |
DOI | 10.1016/j.ejogrb.2014.05.021 |
Alternate Journal | Eur. J. Obstet. Gynecol. Reprod. Biol. |
Citation Key | 495 |
PubMed ID | 24965981 |